Information Provided By: 
Fly News Breaks for September 11, 2017
MRK, INCY, NLNK
Sep 11, 2017 | 07:23 EDT
Stifel analyst Stephen Willey believes recently-updated melanoma data from both NewLink Genetics' (NLNK) phase 2 indoximod program and Incyte (INCY) and Merck's (MRK) ESMO presentation confirm IDO inhibitors are more-than-likely synergizing with PD-1 inhibition, adding that NewLink's drug appears to yield "slightly-better efficacy" in "slightly-healthier" patients. He increased his price target on NewLink to $29 from $14 to reflect favorable risk adjustments and higher melanoma sales estimates and keeps a Buy rating on the stock.
News For NLNK;INCY;MRK From the Last 2 Days
There are no results for your query NLNK;INCY;MRK
